

BIOTECH ANTIBIOTIC



REDAMP

Technology matured by



**ANTIMICROBIAL PEPTIDE (AMP) FOR THE TREATMENT OF
ACINETOBACTER BAUMANNII INFECTIONS**

A.BAUMANNII

ANTIBIORESISTANCE

INFECTIOUS DISEASE

Achievements:

In vivo PK results for IV and IN administration:

- t_{1/2} plasma: 19 min
- t_{1/2} intranasal: 142 min
- DMTIN: 5 mg/kg (200x MIC)
- DMTIV: 40 mg/kg

No cytotoxic on HUVEC cells and keratinocytes / **Absence of hemolysis** on red blood cells /
Good lung exposure


Minimum Inhibitory Concentration: WT strains and clinical strains of *A. baumannii* : 3.25
µg/ml, 1.25 µM

MucilAir™ model of two resistant strains *A. baumannii* : efficacy at 50-100µM

IP status

PCT, Priority date: Dec. 16th 2021 (EP, US, CA)

Effect of AMP on *A. baumannii* (NMD-1) growth in
the apical compartment (MucilAir™ model) at
24h post infection



Alliance Opportunity : Co-development ; Licensing

IP : Patent (<5 years)

TRL : Lead Optimization

CONTACT BUSINESS

Bruna GIOIA | Business Developer SATT | bruna.gioia@sattnord.fr